VS-01 shows promise in Phase Ib decompensated liver cirrhosis trial
The first-in-human trial showed VS-01 is safe and generated improvements in selected biomarkers and clinical cognitive tests in patients with decompensated liver cirrhosis.
List view / Grid view
The first-in-human trial showed VS-01 is safe and generated improvements in selected biomarkers and clinical cognitive tests in patients with decompensated liver cirrhosis.
Aleglitazar improves portal hypertension in rats with cirrhosis by suppressing inflammation, vasoconstriction, and angiogenesis...